Patents Assigned to FRED
  • METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES OR CONDITIONS
    Publication number: 20200115459
    Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to NKG2D receptors present on the surface of cells underlying the disorders.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 16, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Thomas Spies, Veronika Spies
  • Compositions and methods for the treatment of hemoglobinopathies
    Patent number: 10619140
    Abstract: Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) and/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human ?-globin locus; (d) to disrupt a HbF silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbF silencing region; (e) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; (f) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; and/or (g) to correct one or more ?-globin gene mutation(s).
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: April 14, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Ryo Takeuchi, Mark T Groudine, Barry L. Stoddard, Michael A Bender
  • Compositions and methods for detecting allogeneic matter in a subject
    Patent number: 10604805
    Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: March 31, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: J. Lee Nelson, Nathalie C. Lambert, Vijayakrishna K. Gadi, Zhen Yan
  • Circular tandem repeat proteins
    Patent number: 10597466
    Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: March 24, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Philip Bradley, Barry L. Stoddard
  • Method and system for volume estimation of bodily outputs in absorbent articles
    Patent number: 10588787
    Abstract: A method and an incontinence monitoring system for estimating a volume or a volume range of a bodily output in a combination absorbent article and wetness sensor. The system comprises a combination of an absorbent article and a wetness sensor, and a processor adapted to receive an input representative of an electrical variable of the wetness sensor indicative of the occurrence of a bodily output in the absorbent article and to process the input including: characterising the input to generate a vector that is representative of the bodily output, applying one or more functions to the vector to generate one or more possible volumes of the bodily output, generating a distribution of the possible volumes, and determining a volume or a volume range for the bodily output based on the distribution of the possible volumes.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: March 17, 2020
    Assignee: Fred Bergman Healthcare Pty Ltd.
    Inventors: Hadi Mashin-Chi, Mehdi Azimi, Anushiya Arunachalam Kannan
  • System and method for determining a pre-existing characteristic and pre-existing state of an article
    Patent number: 10568778
    Abstract: The present invention relates to systems, methods and devices for determining one or more pre-existing characteristics, pre-existing states or both of a combination absorbent article and electrical circuit after connecting an electronic device to the combination absorbent article and electrical circuit. The method and system is particularly, although not exclusively, suitable for determining pre-existing characteristics such as absorbent article size, type, capacity and a pre-existing state such as whether or not the electrical circuit of the combination absorbent article and electrical circuit has been previously connected to the electronic device or another like electronic device.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: February 25, 2020
    Assignee: Fred Bergman Healthcare Pty Ltd.
    Inventors: Hadi Mashin-Chi, Peter Hubertus Aigner, Peter Curran, Mehdi Azimi, Mohammed Asef Ali
  • BARCODED TRANSPOSASES TO INCREASE EFFICIENCY OF HIGH-ACCURACY GENETIC SEQUENCING
    Publication number: 20200056224
    Abstract: Transposase-based barcoding of DNA for improved efficiency, high-accuracy sequencing is described. Transposases including transposable barcodes can be used to fragment and barcode target DNA in a single step.
    Type: Application
    Filed: April 18, 2018
    Publication date: February 20, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventor: Jason Bielas
  • COMPOSITIONS AND METHODS FOR EXPANSION OF EMBRYONIC HEMATOPOIETIC STEM CELLS
    Publication number: 20200046775
    Abstract: The present invention relates to methods, kits and compositions for expansion of embryonic hematopoietic stem cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGF? pathway. Also provided herein are methods for expanding embryonic hematopoietic stem cells using kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGF? pathway. The embryonic hematopoietic stem cells expanded using the disclosed kits, compositions and methods include cells derived from an embryo (e.g., aorta-gonad-mesonephros region of the embryo), embryonic stem cells, induced pluripotent stem cells, or reprogrammed cells of other types.
    Type: Application
    Filed: October 17, 2019
    Publication date: February 13, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Irwin D. Bernstein, Brandon K. Hadland
  • COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION
    Publication number: 20200030384
    Abstract: The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the HLA antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/progenitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.
    Type: Application
    Filed: October 1, 2019
    Publication date: January 30, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Irwin D. Bernstein, Colleen Delaney
  • Compositions and methods for detecting rare nucleic acid molecule mutations
    Patent number: 10538807
    Abstract: The present disclosure relates to compositions and methods for detecting rare nucleic acid molecule mutations in a plurality of nucleic acid molecules. Also disclosed are methods for determining the size of a nucleic acid molecule using droplet digital PCR.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: January 21, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Jason H. Bielas, Sean D. Taylor, Matthew T. Laurie
  • Compounds and methods for modulation of DUX4
    Patent number: 10538763
    Abstract: The present disclosure pertains generally to double-stranded small interfering RNAs that modulate gene expression for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure provides double-stranded small interfering RNAs that modulate DUX4 gene expression. In certain embodiments, the present disclosure provides methods of inhibiting DUX4 gene expression by contacting a cell with double-stranded small interfering RNAs.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: January 21, 2020
    Assignees: Ionis Pharmaceuticals, Inc., Fred Hutchinson Cancer Research Center
    Inventors: Frank Rigo, Stephen J. Tapscott
  • T cell immunotherapy specific for WT-1
    Patent number: 10538572
    Abstract: The present disclosure provides high affinity and enhanced affinity T cell receptors specific for human Wilms tumor protein 1 (WT-1) epitopes for use in treating diseases or disorders, such as cancer cells that overexpress WT-1.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: January 21, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Thomas M. Schmitt, Philip D. Greenberg, Hieu Nguyen
  • TCRS specific for minor histocompatibility (H) antigen HA-1 and uses thereof
    Patent number: 10538574
    Abstract: The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: January 21, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Marie Bleakley, Robson Dossa, Daniel Sommermeyer
  • METHODS FOR THE TREATMENT OF B CELL MALIGNANCIES USING ADOPTIVE CELL THERAPY
    Publication number: 20200016199
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with chronic lymphocytic leukemia (CLL). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods involve prior administration of a lymphodepleting therapy, such as prior administration of fluradibine and/or another lymphodepleting chemotherapeutic agent, for example cyclophosphamide. In some embodiments, features of the methods include an increase in complete remission, overall survival and/or progression free survival of subjects treated in accord with the provided methods.
    Type: Application
    Filed: June 6, 2017
    Publication date: January 16, 2020
    Applicants: Juno Therapeutics, Inc., Fred Hutchinson Canser Research Center
    Inventors: Cameron J. TURTLE, David MALONEY, Stanley R. RIDDELL, Mark Gilbert
  • IN VIVO GENE THERAPY FOR IMMUNE DEFICIENCIES
    Publication number: 20200009266
    Abstract: In vivo gene therapies for immune deficiencies are described. The in vivo gene therapies utilize a foamy viral vector including a PGK promoter with a therapeutic gene. The foamy viral vector can be beneficially administered with cell mobilization into the peripheral blood.
    Type: Application
    Filed: February 15, 2018
    Publication date: January 9, 2020
    Applicants: Fred Hutchinson Cancer Research Center, Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    Inventors: Frieda Chan, Olivier Humbert, Hans-Peter Kiem, Jennifer E. Adair, David Rawlings, Andrew Scharenberg, Troy Torgerson
  • SYSTEMS AND METHODS FOR HEMATOPOIETIC CELL EXPANSION UTILIZING HYDROGELS
    Publication number: 20200009194
    Abstract: Systems and methods to expand hematopoietic stem cell (HSC) using zwitterionic hydrogels (ZTG) are described. Expansion using the disclosed systems and methods results in HSC populations with (i) an increased proportion of HSC versus partially or fully differentiated cells, (ii) proportionally lower cell surface expression levels of differentiation/maturation markers, (iii) reduced metabolic rates following expansion, and/or (iv) a greater proportion of quiescent cells following expansion, as compared to currently available clinical expansion methods.
    Type: Application
    Filed: January 24, 2018
    Publication date: January 9, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventor: Colleen Delaney
  • SYSTEMS AND METHODS FOR IMMUNOMODULATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS
    Publication number: 20190382725
    Abstract: Systems and methods to modulate the function of mucosal-associated invariant T (MAIT) cells in the absence of a T cell receptor (TCR) signal are described. The systems and methods can be used to elucidate the function of MAIT cells to assess potential therapeutic strategies for conditions associated with inflammation.
    Type: Application
    Filed: January 23, 2018
    Publication date: December 19, 2019
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Martin Prlic, Julia Berkson, Chloe Slichter
  • POINT-OF-CARE AND/OR PORTABLE PLATFORM FOR GENE THERAPY
    Publication number: 20190365817
    Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.
    Type: Application
    Filed: May 24, 2019
    Publication date: December 5, 2019
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Hans-Peter Kiem
  • Tagged chimeric effector molecules and receptors thereof
    Patent number: 10494434
    Abstract: The present disclosure relates to tagged chimeric effector molecules and receptor molecules thereof for genetically engineering a host cell, wherein the recombinant host cell can be identified, isolated, sorted, induced to proliferate, tracked or eliminated using the tag. An exemplary receptor molecule is a chimeric antigen receptor (CAR) having an extracellular domain comprising a binding domain for a target, a hinge region, and a tag cassette, a hydrophobic portion as a transmembrane domain and an intracellular part with an effector domain. An exemplary target is CD19. An exemplary tag is a Strep Tag®. T cells recombinantly modified for expression of such molecules may be used in adoptive immunotherapy.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: December 3, 2019
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Stanley R. Riddell, Lingfeng Liu
  • Compositions for making random codon-mutant libraries and uses thereof
    Patent number: 10479989
    Abstract: The present disclosure relates to compositions and methods for randomly introducing codon-mutations in a target nucleic acid molecule and, more particularly, using wild-type and triplet-randomized oligonucleotides to introduce mutations uniformly across a target nucleotide of interest in a controlled fashion and with a low rate of insertions or deletions.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: November 19, 2019
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Jesse D. Bloom